KFG Wealth Management LLC Has $489,000 Stock Position in Cencora, Inc. (NYSE:COR)

KFG Wealth Management LLC lifted its holdings in Cencora, Inc. (NYSE:COR) by 3.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,171 shares of the company’s stock after purchasing an additional 82 shares during the period. KFG Wealth Management LLC’s holdings in Cencora were worth $489,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of COR. Vanguard Group Inc. acquired a new stake in shares of Cencora in the fourth quarter worth about $4,212,508,000. Price T Rowe Associates Inc. MD acquired a new stake in Cencora in the 1st quarter worth approximately $2,183,619,000. JPMorgan Chase & Co. acquired a new position in Cencora during the first quarter valued at approximately $1,199,695,000. Boston Partners bought a new stake in shares of Cencora during the 1st quarter worth $1,001,269,000. Finally, Capital Research Global Investors acquired a new position in Cencora in the 1st quarter valued at $650,424,000. 97.52% of the stock is currently owned by institutional investors.

Insider Activity at Cencora

In other news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the completion of the sale, the insider now owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. The disclosure for this sale can be found here. Insiders have sold a total of 6,338,756 shares of company stock valued at $1,476,658,274 over the last quarter. 15.80% of the stock is owned by company insiders.

Cencora Stock Performance

COR traded up $1.44 on Friday, hitting $238.11. 1,013,198 shares of the stock traded hands, compared to its average volume of 1,384,765. The business has a fifty day moving average price of $231.19 and a two-hundred day moving average price of $232.64. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.93. The firm has a market capitalization of $47.49 billion, a PE ratio of 26.05, a P/E/G ratio of 1.68 and a beta of 0.45. Cencora, Inc. has a 52 week low of $171.65 and a 52 week high of $247.66.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. Cencora’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.92 earnings per share. On average, research analysts predict that Cencora, Inc. will post 13.56 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 26th. Stockholders of record on Friday, August 9th will be given a dividend of $0.51 per share. The ex-dividend date of this dividend is Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.86%. Cencora’s dividend payout ratio (DPR) is currently 22.32%.

Analyst Ratings Changes

COR has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Robert W. Baird boosted their price objective on Cencora from $285.00 to $287.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Citigroup increased their target price on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. SVB Leerink reaffirmed an “outperform” rating and issued a $275.00 price target on shares of Cencora in a research report on Thursday, June 27th. Finally, StockNews.com upgraded Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average target price of $254.57.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.